Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for Herpes Simplex Keratitis
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on Herpes Simplex Keratitis or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on Herpes Simplex Keratitis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via firstname.lastname@example.org
Oral antivirals for preventing recurrent herpessimplexkeratitis in people with corneal grafts. Ocular herpes is a viral infection of the eye caused by the herpessimplex virus (HSV), a double-stranded DNA virus. Corneal scarring caused by herpessimplexkeratitis (HSK) is the leading infectious cause of penetrating corneal graft in high-income countries. Acyclovir is an antiviral drug known to have a protective effect against recurrences in herpetic eye disease. While there are some studies (...) which have evaluated the effects of intervention with oral antiviral in preventing such recurrences in people with corneal grafts, a systematic review of all comparative clinical trials has not been previously undertaken.To assess the efficacy of oral antivirals such as acyclovir in any dosage when taken for six months or more, in preventing recurrence of herpetic keratitis in people having corneal graft surgery for herpetic keratitis.We searched CENTRAL (which contains the Cochrane Eyes and Vision
What Is the Most Effective Treatment of HerpesSimplexKeratitis? TAKE-HOME MESSAGE Treatmentofherpessimplexviruskeratitiscanbeaccomplishedwitheithertopical tri?uridineorganciclovir,whichhavesimilaref?cacy.Oralacyclovirisanacceptable treatment option in cases for which compliance with a topical ophthalmic regimen may be of concern. What Is the Most Effective Treatment of HerpesSimplexKeratitis? EBEM Commentators Joshua Bucher, MD Rutgers–Robert Wood Johnson Medical School New Brunswick, NJ (...) % con?dence interval [CI] 0.8 to 1.1). 1 Similarly, there was no difference in the primary outcome between interferon treatment and antivirals (RR 1.2; 95% CI 0.9 to 1.6). Commentary It is estimated that herpessimplex virus keratitis has an incidence of approximately12to31peopleper 100,000 annually. 2,3 Although it is a relatively uncommon diagno- sis in the emergency department setting, initiation of appropriate treatment is critical, given the potential to lead to serious visual impairment
Therapeutic interventions for herpessimplex virus epithelial keratitis. Many clinical trials have been performed on the acute treatment of dendritic epithelial keratitis. Surveys of ocular antiviral pharmacology and of herpessimplex virus (HSV) eye disease have evaluated different interventions, but a systematic review of all comparative clinical studies has not previously been undertaken.The objective of this review was to compare the effects of various therapeutic interventions (...) after trial enrolment.This review included data from 98 trials that randomised a total of 5211 participants. Compared to idoxuridine, the topical application of vidarabine, trifluridine, or acyclovir resulted in a significantly greater proportion of participants healing within one week of treatment. Among these latter three antiviral agents, no treatment emerged as significantly better for the therapy of dendritic epithelial keratitis. Insufficient placebo-controlled studies were available to assess
Evidence-based treatment of herpessimplex virus keratitis: a systematic review Evidence-based treatment of herpessimplex virus keratitis: a systematic review Evidence-based treatment of herpessimplex virus keratitis: a systematic review Guess S, Stone D U, Chodosh J CRD summary This review concluded that trifluridine, acyclovir and possibly interferon were effective for herpessimplex virus epithelial keratitis. Corticosteroids with an antiviral were effective for Herpessimplex virus (...) stromal keratitis and long-term acyclovir reduced recurrence. The validity of these conclusions may be limited by the small size of studies, restriction to articles published in English and the method of data extraction. Authors' objectives To systematically review randomised controlled trials for Herpessimplex virus epithelial and stromal keratitis in order to establish an evidence-based foundation for treatment. Searching MEDLINE was searched from January 1966 to May 2006 for studies published
Interventions for herpessimplex virus epithelial keratitis. Many clinical trials have been performed on the acute treatment of dendritic epithelial keratitis. Surveys of antiviral pharmacology and of herpessimplex virus eye disease have evaluated different commercially available agents, but a systematic review of all comparative clinical studies has not previously been undertaken.The objective of this review is to compare the effects of various treatments for dendritic or geographic herpes (...) antiviral agents are effective and nearly equivalent, but the combination of an antiviral nucleoside and interferon seems to speed healing. Future trials of the acute treatment of herpessimplex virus epithelial keratitis must aim to achieve adequate statistical power for assessing the primary outcome and should consider the effect of lesion size and other characteristics on treatment response.